{"id":"truvada-pill","safety":{"commonSideEffects":[{"rate":"10-15","effect":"Nausea"},{"rate":"10-15","effect":"Diarrhea"},{"rate":"5-10","effect":"Headache"},{"rate":"5-10","effect":"Fatigue"},{"rate":null,"effect":"Renal impairment (with long-term use)"},{"rate":null,"effect":"Bone density loss"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Truvada contains tenofovir disoproxil fumarate (TDF) and emtricitabine (FTC), which are nucleoside reverse transcriptase inhibitors (NRTIs) that inhibit HIV reverse transcriptase, an enzyme essential for viral replication. When used as pre-exposure prophylaxis (PrEP), it prevents HIV infection in high-risk individuals by maintaining suppressive drug levels in genital and rectal tissues. The combination is also used as part of antiretroviral therapy in HIV-infected patients to suppress viral load.","oneSentence":"Truvada is a fixed-dose combination of two nucleoside reverse transcriptase inhibitors that blocks HIV reverse transcriptase to prevent viral replication.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:35:39.994Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"HIV pre-exposure prophylaxis (PrEP) in high-risk individuals"},{"name":"HIV-1 infection treatment as part of combination antiretroviral therapy"}]},"trialDetails":[{"nctId":"NCT04898699","phase":"EARLY_PHASE1","title":"IPrEP Men's Study: Expanding the Reach of Prevention for Men in Kisumu, Kenya","status":"COMPLETED","sponsor":"Columbia University","startDate":"2021-11-24","conditions":"HIV","enrollment":120},{"nctId":"NCT03512418","phase":"PHASE3","title":"Development of Ingestible Biosensors to Enhance PrEP Adherence in Substance Users (PrEPSteps)","status":"COMPLETED","sponsor":"Brigham and Women's Hospital","startDate":"2019-06-20","conditions":"HIV Infections, Substance Use Disorders","enrollment":30},{"nctId":"NCT01234116","phase":"PHASE4","title":"Post-Exposure Prophylaxis in Health Care Workers","status":"COMPLETED","sponsor":"Henry Ford Health System","startDate":"2011-02","conditions":"Human Immunodeficiency Virus","enrollment":16},{"nctId":"NCT04884139","phase":"PHASE4","title":"DTG/3TC vs. BIC/FTC/TAF Maintenance Therapy in People Living With HIV:","status":"COMPLETED","sponsor":"Fundacion SEIMC-GESIDA","startDate":"2021-07-14","conditions":"HIV-1-infection","enrollment":554},{"nctId":"NCT05813964","phase":"PHASE3","title":"Efficacy, Acceptability and Safety of Event-driven HIV PrEP Using TAF/FTC in MSM in Thailand and France.","status":"RECRUITING","sponsor":"ANRS, Emerging Infectious Diseases","startDate":"2024-06-05","conditions":"HIV/AIDS","enrollment":524},{"nctId":"NCT05072093","phase":"PHASE4","title":"Parrying the Pitfalls of PrEP: Project PEACH","status":"COMPLETED","sponsor":"Emory University","startDate":"2021-11-20","conditions":"HIV, STI","enrollment":240},{"nctId":"NCT05378399","phase":"PHASE3","title":"SmartSteps: A Context-Aware, PrEP Adherence Intervention for Individuals With Substance Use Disorder","status":"RECRUITING","sponsor":"Brigham and Women's Hospital","startDate":"2022-12-20","conditions":"HIV Infections, Substance Use, Adherence, Medication","enrollment":40},{"nctId":"NCT04442737","phase":"PHASE4","title":"A Study of Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (D/C/F/TAF) Evaluated as a Fixed Dose Combination Regimen in Participants Switching From an Integrase Inhibitor Who Have Experienced Rapid Weight Gain","status":"COMPLETED","sponsor":"Janssen Scientific Affairs, LLC","startDate":"2020-07-01","conditions":"HIV-1","enrollment":103},{"nctId":"NCT01140880","phase":"PHASE2","title":"Biobehavioral Interventions for HIV-negative, Stimulant Using Men Who Have Sex With Men","status":"COMPLETED","sponsor":"Friends Research Institute, Inc.","startDate":"2010-05","conditions":"HIV Seroconversion, Stimulant Abuse","enrollment":170},{"nctId":"NCT04585737","phase":"PHASE4","title":"Efficacy of Switching to DTG/3TC in Virologically-suppressed Adults Currently on B/F/TAF","status":"COMPLETED","sponsor":"Charlotte-Paige Rolle, MD","startDate":"2020-10-05","conditions":"HIV I Infection","enrollment":222},{"nctId":"NCT05592613","phase":"PHASE3","title":"Next Generation Ingestible Sensors for Medication Adherence Measurement","status":"COMPLETED","sponsor":"Brigham and Women's Hospital","startDate":"2023-02-06","conditions":"HIV Infection, Adherence, Medication, Adherence, Treatment","enrollment":15},{"nctId":"NCT04298697","phase":"PHASE4","title":"Biomarkers for Event-driven PrEP Adherence","status":"COMPLETED","sponsor":"Emory University","startDate":"2020-02-28","conditions":"Human Immunodeficiency Virus","enrollment":43},{"nctId":"NCT03502005","phase":"PHASE4","title":"Efficacy, Safety & Tolerability of Switching EFV/TDF/FTC to BIC/FTC/TAF in Virologically Suppressed Adults With HIV-1","status":"COMPLETED","sponsor":"Midland Research Group, Inc.","startDate":"2018-03-01","conditions":"Human Immunodeficiency Virus","enrollment":100},{"nctId":"NCT06465862","phase":"NA","title":"Development of a Silica Microparticle Taggant System to Measure ART Adherence","status":"NOT_YET_RECRUITING","sponsor":"Brigham and Women's Hospital","startDate":"2024-09-15","conditions":"Hiv, Medication Adherence, Compliance, Medication","enrollment":15},{"nctId":"NCT02621242","phase":"","title":"Effects of the Anti-HIV Pill Truvada on Gene Transcription in the Gastrointestinal Tract of HIV-uninfected Individuals","status":"COMPLETED","sponsor":"University of Washington","startDate":"2015-12","conditions":"HIV","enrollment":9},{"nctId":"NCT05243602","phase":"PHASE4","title":"BFTAF Elderly Switch Study","status":"COMPLETED","sponsor":"University of Nairobi","startDate":"2022-02-01","conditions":"HIV-1-infection","enrollment":520},{"nctId":"NCT06273943","phase":"PHASE3","title":"Impact of Long-acting Injectable Cabotegravir for HIV PrEP in MSM in France.","status":"NOT_YET_RECRUITING","sponsor":"ANRS, Emerging Infectious Diseases","startDate":"2024-04-01","conditions":"Prevention","enrollment":322},{"nctId":"NCT04549467","phase":"PHASE4","title":"Efficacy of Dolutegravir Plus Lamivudine in HIV-1-infected Treatment-naïve Adults Without a Baseline Genotyping Test","status":"COMPLETED","sponsor":"Fundacion IDEAA","startDate":"2020-11-17","conditions":"Hiv, HIV-1-infection","enrollment":244},{"nctId":"NCT03493568","phase":"PHASE3","title":"Switch From Dual Regimens Based on Dolutegravir Plus a Reverse Transcriptase Inhibitor to E/C/F/TAF in Virologically Suppressed, HIV-1 Infected Patients (Be-OnE)","status":"TERMINATED","sponsor":"IRCCS San Raffaele","startDate":"2017-02-06","conditions":"HIV-1-infection","enrollment":100},{"nctId":"NCT04778527","phase":"NA","title":"A Crossover Adherence and Acceptability Study Assessing a DPP Capsule for HIV and Pregnancy Prevention","status":"UNKNOWN","sponsor":"Population Council","startDate":"2022-09-13","conditions":"HIV Infections","enrollment":96},{"nctId":"NCT04778514","phase":"NA","title":"A Crossover Acceptability Study Assessing a DPP Capsule for HIV and Pregnancy Prevention","status":"COMPLETED","sponsor":"Population Council","startDate":"2022-12-07","conditions":"HIV Infections, Contraception","enrollment":30},{"nctId":"NCT04870671","phase":"EARLY_PHASE1","title":"Project ADHERE: Clinical Proof-of-Concept of a Tenofovir (TFV) Aptamer-Based Biosensor","status":"COMPLETED","sponsor":"Eastern Virginia Medical School","startDate":"2021-03-25","conditions":"HIV/AIDS, Adherence, Medication, Drug Use","enrollment":14},{"nctId":"NCT03842436","phase":"PHASE4","title":"Feasibility and Acceptability of Digital Pills to Monitor PrEP Adherence in MSM With Substance Use","status":"COMPLETED","sponsor":"Brigham and Women's Hospital","startDate":"2018-10-01","conditions":"HIV/AIDS, Substance Use Disorders, Adherence, Medication","enrollment":16},{"nctId":"NCT03532425","phase":"PHASE4","title":"B/F/TAF vs Atripla Double-Blind Switch Study in HIV-1 Infected Adults","status":"TERMINATED","sponsor":"University of Alberta","startDate":"2018-10-29","conditions":"HIV-1-infection","enrollment":28},{"nctId":"NCT03512964","phase":"NA","title":"Rapid HIV Treatment Initiation, Access and Engagement in Care","status":"COMPLETED","sponsor":"Johns Hopkins University","startDate":"2016-11-29","conditions":"Human Immunodeficiency Virus","enrollment":32},{"nctId":"NCT03113123","phase":"NA","title":"Prevention of HIV in \"Île-de-France\"","status":"UNKNOWN","sponsor":"ANRS, Emerging Infectious Diseases","startDate":"2017-05-03","conditions":"HIV Infections","enrollment":3257},{"nctId":"NCT02322099","phase":"PHASE4","title":"Alendronate for Prevention of AntiRetroviral Therapy-associated Bone Loss","status":"TERMINATED","sponsor":"University College Dublin","startDate":"2016-05","conditions":"Bone Demineralization","enrollment":53},{"nctId":"NCT03499483","phase":"PHASE4","title":"Biktarvy for Non-Occupational Post-Exposure Prophylaxis (nPEP)","status":"COMPLETED","sponsor":"Fenway Community Health","startDate":"2019-01-24","conditions":"HIV Prevention","enrollment":52},{"nctId":"NCT04359095","phase":"PHASE2, PHASE3","title":"Effectiveness and Safety of Medical Treatment for SARS-CoV-2 (COVID-19) in Colombia","status":"COMPLETED","sponsor":"Universidad Nacional de Colombia","startDate":"2020-08-18","conditions":"COVID-19","enrollment":650},{"nctId":"NCT04483674","phase":"PHASE2","title":"Bictegravir/FTC/TAF for the Treatment of Primary HIV Infection","status":"UNKNOWN","sponsor":"Anna Cruceta","startDate":"2020-12-04","conditions":"HIV Primary Infection","enrollment":66},{"nctId":"NCT02870790","phase":"PHASE3","title":"Expanded PrEP Implementation in Communities in NSW","status":"COMPLETED","sponsor":"Kirby Institute","startDate":"2016-03","conditions":"HIV, STI","enrollment":9733},{"nctId":"NCT00627055","phase":"PHASE4","title":"Second-line Therapy Antiretroviral in Patients Who Failed Non-nucleoside Reverse Transcriptase Inhibitor (NNRTI) - Based Regimens","status":"COMPLETED","sponsor":"The HIV Netherlands Australia Thailand Research Collaboration","startDate":"2008-05","conditions":"HIV Infections","enrollment":200},{"nctId":"NCT03012607","phase":"NA","title":"Tenofovir Adherence to Rapidly Guide and Evaluate PrEP and HIV Therapy","status":"COMPLETED","sponsor":"University of Washington","startDate":"2017-01","conditions":"Hiv","enrollment":30},{"nctId":"NCT03218592","phase":"PHASE4","title":"ENLIGHTEN: Establishing Novel Antiretroviral (ARV) Imaging for Hair to Elucidate Non-Adherence","status":"COMPLETED","sponsor":"University of North Carolina, Chapel Hill","startDate":"2017-06-28","conditions":"HIV/AIDS","enrollment":36},{"nctId":"NCT02985996","phase":"PHASE1","title":"Body Compartment PK for New HIV Pre-exposure Prophylaxis Modalities","status":"COMPLETED","sponsor":"Emory University","startDate":"2017-02-06","conditions":"HIV Infections","enrollment":48},{"nctId":"NCT02022657","phase":"PHASE1, PHASE2","title":"Pre-Exposure Prophylaxis (PrEP) Adherence Monitoring Using Dried Blood Spots","status":"COMPLETED","sponsor":"University of Colorado, Denver","startDate":"2014-04","conditions":"PrEP Adherence Monitoring","enrollment":52},{"nctId":"NCT03877536","phase":"NA","title":"Antiretroviral Therapy for Acute HIV Infection","status":"WITHDRAWN","sponsor":"Henry M. Jackson Foundation for the Advancement of Military Medicine","startDate":"2019-03-17","conditions":"HIV Infections","enrollment":""},{"nctId":"NCT03142256","phase":"PHASE4","title":"3Ps for Prevention Study (Perception, Partners, Pills)","status":"UNKNOWN","sponsor":"Desmond Tutu HIV Centre","startDate":"2017-03-24","conditions":"Adherence","enrollment":200},{"nctId":"NCT00442962","phase":"PHASE4","title":"HIV Treatment Reinitiation in Women Who Received Anti-HIV Drugs to Prevent Mother-to-Child Transmission of HIV","status":"COMPLETED","sponsor":"Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections","startDate":"2007-05","conditions":"HIV Infections","enrollment":54},{"nctId":"NCT01605890","phase":"PHASE2","title":"Trial Evaluating a First Line Combination Therapy With Raltegravir, Emtricitabine and Tenofovir in HIV-2 Infected Patients","status":"COMPLETED","sponsor":"ANRS, Emerging Infectious Diseases","startDate":"2012-07","conditions":"HIV-2 Infection","enrollment":30},{"nctId":"NCT01033942","phase":"PHASE2","title":"Pre-Exposure Prophylaxis in YMSM","status":"COMPLETED","sponsor":"University of North Carolina, Chapel Hill","startDate":"2009-08","conditions":"HIV","enrollment":68},{"nctId":"NCT01285050","phase":"PHASE4","title":"Interferon Alfa Sensitivity in HIV/HCV Persons Before and After HIV Meds","status":"COMPLETED","sponsor":"Johns Hopkins University","startDate":"2011-01","conditions":"HIV Infection, Hepatitis C","enrollment":20},{"nctId":"NCT00856323","phase":"PHASE2","title":"Contingency Management for Methamphetamine Abstinence and HIV Post-Exposure Prophylaxis in Men Who Have Sex With Men","status":"COMPLETED","sponsor":"Friends Research Institute, Inc.","startDate":"2009-01","conditions":"Amphetamine-Related Disorders, HIV, HIV Infections","enrollment":53},{"nctId":"NCT00959894","phase":"PHASE2","title":"Evaluating Once Daily Etravirine in Treatment-Naive Adults With HIV Infection","status":"COMPLETED","sponsor":"University of North Carolina, Chapel Hill","startDate":"2009-09","conditions":"HIV Infections","enrollment":80},{"nctId":"NCT01322932","phase":"","title":"Tenofovir, Emtricitabine and Efavirenz Late Switch to a Single Pill: Patients' Opinion Survey","status":"COMPLETED","sponsor":"Center for Primary Care and Public Health (Unisante), University of Lausanne, Switzerland","startDate":"2010-07","conditions":"HIV Infection","enrollment":95},{"nctId":"NCT00669487","phase":"PHASE3","title":"A 72-week Randomized Clinical Trial Comparing the Safety and Efficacy of Three Initial Antiretroviral Regimens -GPO-VIR S (d4T/3TC/NVP) for 24 Weeks Followed by GPO-VIR Z (AZT/3TC/NVP) vs GPO-VIR Z vs TDF/FTC/NVP","status":"COMPLETED","sponsor":"SEARCH Research Foundation","startDate":"2008-04","conditions":"HIV Infections","enrollment":150},{"nctId":"NCT00302822","phase":"PHASE3","title":"Intensification With Enfuvirtide in Naive HIV-infected Patients (ANRS130)","status":"COMPLETED","sponsor":"French National Agency for Research on AIDS and Viral Hepatitis","startDate":"2006-04","conditions":"HIV Infections, AIDS","enrollment":195},{"nctId":"NCT01697046","phase":"PHASE3","title":"A Pilot Study on Raltegravir, Tenofovir and Emtricitabine for Peri-exposure Prophylaxis for HIV Infection","status":"UNKNOWN","sponsor":"Projeto Praça Onze","startDate":"2012-11","conditions":"Infection, HIV","enrollment":65},{"nctId":"NCT01005290","phase":"PHASE2","title":"A Pharmacodynamic Study to Evaluate the Effect of a Fixed Dose Combination Pill on Blood Pressure","status":"TERMINATED","sponsor":"Ferrer Internacional S.A.","startDate":"2009-10","conditions":"Hypertension","enrollment":38},{"nctId":"NCT00936195","phase":"PHASE3","title":"Universal Use of EFV-TDF-FTC and AZT-3TC-LPV/r Combinations for HIV-1 PMTCT in Pregnant and Breastfeeding Women : a Phase 3 Trial","status":"WITHDRAWN","sponsor":"French National Agency for Research on AIDS and Viral Hepatitis","startDate":"2010-01","conditions":"HIV Infection, Pregnancy, Breastfeeding","enrollment":""},{"nctId":"NCT00528060","phase":"PHASE2","title":"Measure of Pharmacokinetic Parameters and Adherence With MEMS in Naive HIV Infected Patients Treated With Reyataz Once Daily Combined With Norvir and Truvada","status":"COMPLETED","sponsor":"French National Agency for Research on AIDS and Viral Hepatitis","startDate":"2008-01","conditions":"HIV Infections","enrollment":35},{"nctId":"NCT00112047","phase":"PHASE3","title":"Tenofovir Disoproxil Fumarate/Emtricitabine/Efavirenz Versus Combivir/Efavirenz in Antiretroviral-Naive HIV-1 Infected Subjects","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2003-07","conditions":"HIV Infections","enrollment":517}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":270,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Tenofovir/Emtricitabine"],"phase":"marketed","status":"active","brandName":"Truvada Pill","genericName":"Truvada Pill","companyName":"University of North Carolina, Chapel Hill","companyId":"university-of-north-carolina-chapel-hill","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Truvada is a fixed-dose combination of two nucleoside reverse transcriptase inhibitors that blocks HIV reverse transcriptase to prevent viral replication. Used for HIV pre-exposure prophylaxis (PrEP) in high-risk individuals, HIV-1 infection treatment as part of combination antiretroviral therapy.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}